PA8429201A1 - Virosomas cationicos como sistema de transferencia para material genetico - Google Patents

Virosomas cationicos como sistema de transferencia para material genetico

Info

Publication number
PA8429201A1
PA8429201A1 PA19978429201A PA8429201A PA8429201A1 PA 8429201 A1 PA8429201 A1 PA 8429201A1 PA 19978429201 A PA19978429201 A PA 19978429201A PA 8429201 A PA8429201 A PA 8429201A PA 8429201 A1 PA8429201 A1 PA 8429201A1
Authority
PA
Panama
Prior art keywords
genetic material
transfer system
cells
virosomes
cationic virosomes
Prior art date
Application number
PA19978429201A
Other languages
English (en)
Spanish (es)
Inventor
Peter Klein
Reinhard Glueck
Ernst Rudolf Waelti
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of PA8429201A1 publication Critical patent/PA8429201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PA19978429201A 1996-05-08 1997-05-08 Virosomas cationicos como sistema de transferencia para material genetico PA8429201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96107282 1996-05-08

Publications (1)

Publication Number Publication Date
PA8429201A1 true PA8429201A1 (es) 2000-05-24

Family

ID=8222763

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19978429201A PA8429201A1 (es) 1996-05-08 1997-05-08 Virosomas cationicos como sistema de transferencia para material genetico

Country Status (28)

Country Link
US (1) US6210708B1 (Direct)
EP (1) EP0902682A2 (Direct)
JP (1) JP2000509404A (Direct)
KR (1) KR100536983B1 (Direct)
CN (1) CN1271992C (Direct)
AR (1) AR007054A1 (Direct)
AU (1) AU710170B2 (Direct)
BG (1) BG102880A (Direct)
BR (1) BR9709224A (Direct)
CA (1) CA2253561A1 (Direct)
CO (1) CO4600638A1 (Direct)
CZ (1) CZ299809B6 (Direct)
EA (1) EA003130B1 (Direct)
GT (1) GT199700058A (Direct)
HR (1) HRP970234B1 (Direct)
HU (1) HUP9901790A3 (Direct)
ID (1) ID17934A (Direct)
NO (1) NO327726B1 (Direct)
NZ (1) NZ332666A (Direct)
OA (1) OA10916A (Direct)
PA (1) PA8429201A1 (Direct)
PE (1) PE65198A1 (Direct)
PL (1) PL199201B1 (Direct)
SK (1) SK152698A3 (Direct)
SV (1) SV1997000032A (Direct)
TN (1) TNSN97080A1 (Direct)
WO (1) WO1997041834A1 (Direct)
ZA (1) ZA973885B (Direct)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113347A1 (en) * 1991-05-08 2003-06-19 Schweiz. Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
EP1011735A1 (en) * 1997-09-08 2000-06-28 Promega Corporation METHOD OF $i(IN VIVO) TRANSFORMATION UTILIZING LIPID VEHICLES
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
GB9813100D0 (en) * 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
CA2388053A1 (en) * 1999-10-08 2001-04-19 Nika Health Products Limited Cationic dosper virosomes
WO2001044023A1 (de) * 1999-12-17 2001-06-21 Duerschinger Guenter Induktiv aktivierbare zündkapsel für insassen-rückhaltesysteme und prüfschaltung für diese zündkapsel
US20030139361A1 (en) * 2000-01-21 2003-07-24 Kazuhiro Yuda Drug for gene therapy
JP2004536607A (ja) * 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
KR100411234B1 (ko) * 2001-08-14 2003-12-18 한국과학기술원 올리고뉴클레오티드 혼성화 미셀 및 그의 제조방법
WO2003038103A1 (en) * 2001-10-29 2003-05-08 Atso Raasmaja Method for gene transfection using synergistic combinations of cationic lipids and cationic polymers
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
EA008497B1 (ru) * 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070172520A1 (en) * 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
EP2064229B1 (en) * 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Oncolytic rhabdovirus
KR101242113B1 (ko) * 2010-10-22 2013-03-19 고마바이오텍(주) 유전자 전달용 양이온성 센다이 ｆ／ｈｎ 바이로좀 복합체
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
US20140335117A1 (en) * 2011-10-07 2014-11-13 Skau Aps Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
MX383392B (es) 2016-09-27 2025-03-13 Camurus Ab Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
AU655823B2 (en) * 1991-05-08 1995-01-12 Crucell Switzerland Ag Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU3614493A (en) 1992-02-04 1993-09-01 Chiron Corporation Non-toxic lipid vaccine formulations
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
EP0762870B1 (en) * 1994-05-31 2002-09-11 INEX Pharmaceutical Corp. Virosome-mediated intracellular delivery of therapeutic agents
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale

Also Published As

Publication number Publication date
HUP9901790A2 (hu) 1999-08-30
EA003130B1 (ru) 2003-02-27
EA199800992A1 (ru) 1999-06-24
NO985137D0 (no) 1998-11-04
CN1225007A (zh) 1999-08-04
CO4600638A1 (es) 1998-05-08
KR20000010780A (ko) 2000-02-25
AU710170B2 (en) 1999-09-16
EP0902682A2 (en) 1999-03-24
BR9709224A (pt) 1999-08-10
NZ332666A (en) 2000-05-26
BG102880A (en) 1999-05-31
KR100536983B1 (ko) 2006-06-29
ZA973885B (en) 1998-11-06
ID17934A (id) 1998-02-12
CN1271992C (zh) 2006-08-30
CA2253561A1 (en) 1997-11-13
CZ299809B6 (cs) 2008-12-03
NO327726B1 (no) 2009-09-14
OA10916A (en) 2003-02-21
CZ361498A3 (cs) 1999-03-17
HRP970234B1 (en) 2002-04-30
US6210708B1 (en) 2001-04-03
PE65198A1 (es) 1998-10-16
AR007054A1 (es) 1999-10-13
AU2776697A (en) 1997-11-26
PL329853A1 (en) 1999-04-12
HRP970234A2 (en) 1998-06-30
PL199201B1 (pl) 2008-08-29
HUP9901790A3 (en) 2010-11-29
NO985137L (no) 1999-01-04
GT199700058A (es) 1998-10-29
TNSN97080A1 (fr) 2005-03-15
SV1997000032A (es) 1998-03-27
WO1997041834A1 (en) 1997-11-13
JP2000509404A (ja) 2000-07-25
SK152698A3 (en) 1999-05-07

Similar Documents

Publication Publication Date Title
PA8429201A1 (es) Virosomas cationicos como sistema de transferencia para material genetico
ES2195998T3 (es) Sistemas de expresion de dna basados en alfavirus.
AR077576A2 (es) Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos
AR004860A1 (es) Anticuerpos mono o policionales, anticuerpos conjugados, o sus fragmentos, su utilizacion y metodo de diagnostico in vitro de patologias correlacionadas con una expresion anormal del receptor de la il-13, a partir de muestras biologicas susceptibles de contener el receptor de la il-13 expresado a un nivel anormal
FI963103A7 (fi) Ei-virusvektori
SV1997000071A (es) Serie de celulas inmortalizadas para el cultivo de virus
ES2076160T3 (es) Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante.
CY1105282T1 (el) Διαγνωση της κοιλιοκακης με τη χρηση ενος επιτοπιου της γλιαδινης
ATE198980T1 (de) Bioabbaubare polymere zur zelltransplantation
CO5580816A2 (es) Metodos para la preparacion de o-desmetilvenlafaxina
BR9815142A (pt) "proteìna isolada e modificada; vesicula; método de geração de um complexo proteìco multivalente; de modificação de uma proteìna; de tratamento de um disturbio neurológico; de alteração do estado de crescimento de uma célula; complexo proteìco; polipeptideo de ouriço; polipeptideo de ouriço modificado; proteìna sintética recombinante e uso terapêutico da proteìna"
ES8202586A1 (es) Un procedimiento para clonar una secuencia de desoxinucleo- tidos
BR0011033A (pt) Métodos de purificação de dna e dna purificado
BR9811675A (pt) Genes isolados para proteìna da membrana de célula dentrìtica
CR6683A (es) Sistema de entrega de quelator de hierro
DK0904282T3 (da) Hidtil ukendte kationiske cholesterylderivater indeholdende cykliske polære grupper
AR011994A1 (es) Secuencia aislada de acidos nucleicos, vector para la distribucion de dicha secuencia aislada de acidos nucleicos, celula huesped, planta y metodo
BR9813099A (pt) Seleção positiva-negativa na recombinação homóloga
AR027762A1 (es) Acidos nucleicos aislados de plasmido pmr2 de micromonospora rosaria y vectores preparados a partir de los mismos
ATE246935T1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
DK0986568T3 (da) Kationiske midler til transfektion af nukleinsyrer
ECSP972105A (es) Virosomas cationicos como sistema de transferencia para material genetico
BR0005721A (pt) Plasmìdeos de corynebacterium glutamicum e uso dos mesmos
ES8305829A1 (es) Un procedimiento para la produccion de una proteina de fusion.
Sanger et al. Unusual cleavage furrows in vertebrate tissue culture cells: insights into the mechanisms of cytokinesis